Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 3/20 | 0.38 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470762 | 0.81 | PNMT (0.55) | MAOAMAOBAKT2PNMTTAAR1 | |
| SCHEMBL1824822 | 0.81 | MAOA (0.52) | MAOAMAOBAKT2PNMTTAAR1 | |
| Hydrochloric Acid SCHEMBL3913879 | 0.80 | PNMT (0.53) | MAOAMAOBAKT2PNMTTAAR1 | |
| SCHEMBL736963 | 0.79 | ALDH1A1 (0.42) | MAOAMAOBAKT2PNMTTAAR1 | |
| SCHEMBL736321 | 0.79 | MAOA (0.41) | MAOAMAOBAKT2PNMTTAAR1 | |
| SCHEMBL31118093 | 0.77 | PNMT (0.38) | PNMTFFAR4MPOTAAR1AKR1B1 | |
| SCHEMBL3163919 | 0.76 | FFAR4 (0.41) | FFAR4P2RX7 | |
| SCHEMBL2468659 | 0.75 | TAAR1 (0.55) | MAOAMAOBAKT2TAAR1 | |
| SCHEMBL1822591 | 0.75 | MAOA (0.48) | MAOAMAOBAKT2PNMTTAAR1 | |
| SCHEMBL559225 | 0.74 | PNMT (0.67) | PNMTMPOTAAR1AKR1B1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138340-B2 | Bicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-20 | — | — | US | disclosed |
| EP-1786814-B1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20090306123-A1 | Bicyclononene derivaties | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306123-A1 | Bicyclononene derivaties | REN, ACE, CYP51A1 | MAOA 483/4885MAOB 381/4885AKT2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.